Obermatt

Genus

LSE:GNS · GB0002074580
BiotechnologyMedium

360

67
EV / EBIT55
Price / Owner Earnings5
Owner Earnings Yield90
Dividend Yield97
Price/Sales83
EV / Gross Profit81
Price/Book42
Return on Capital86
Cash Return on Capital91
Return on Equity91
EBIT Margin76
Gross Profitability79
Accruals44
Owner Earnings Margin89
Sales growth29
Profit Growth86
Long-Term EPS Growth57
Reinvestment34
Price momentum59
Debt load39
Refinancing88
Debt Payback29
Liquidity78
Analyst ratings41
Opinion Changes50
Price Target Upside30
Market mood15
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Genus clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUK
IndustryBiotechnology
SizeMedium
TypePublic Company
ExchangeLSE
Founded1994
Employees453
ISINGB0002074580
Last UpdateApr 2, 2026
Themes
Animal FeedLivestockAgriTechGeneticsFarmingBiotechnologyHealth Care

Description

Genus plc (Genus), a global animal genetics company, pioneers the improvement of livestock through research and development. The company focuses on developing genetic products for farmers worldwide, primarily in the porcine and bovine sectors. Busin…

Analysis

Quality compounder

Genus plc is a quality compounder: a well-run business trading at a price that reflects what it is worth.

The price is expensive. You pay 29.8× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone. At today's price, the market is assuming roughly 12% yearly growth; analysts expect 14%. The price, in other words, assumes less than the experts do.

The trajectory is moderate and the balance sheet is adequate. The company scores 12/20 on our value-creation score: creating some value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
96
2026

All-time high

100

Feb 2026

All-time low

92

Mar 2026

Average rank

96

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
83
Price/Earnings
19
Price/Book
42
Dividend Yield
97
Value (overall)
97

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Genus with its peers
ProQR Therapeutics
NAQ:PRQR
19
CountryNetherlands
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
ABIVAX
PAR:ABVX
26
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Uniqure
NSQ:QURE
20
CountryNetherlands
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Pharming
AEX:PHARM
77
CountryNetherlands
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
MDxHealth
NAQ:MDXH
43
CountryBelgium
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Kuros Biosciences
SWX:KURN
80
CountrySwitzerland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →